<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01524068</url>
  </required_header>
  <id_info>
    <org_study_id>PRO12010444</org_study_id>
    <nct_id>NCT01524068</nct_id>
  </id_info>
  <brief_title>A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations</brief_title>
  <official_title>A Multicenter, Open-Label, Phase II Study of Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids in Patients With Acute Idiopathic Pulmonary Fibrosis Exacerbations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, multi-center, open-label Phase II clinical trial to determine the&#xD;
      efficacy of combined plasma exchange (PEX), rituximab, and conventional corticosteroid&#xD;
      administration, in comparison to corticosteroids alone, among patients with acute Idiopathic&#xD;
      Pulmonary Fibrosis (IPF) exacerbations.&#xD;
&#xD;
      The investigators central hypothesis is that antibody-mediated autoimmunity can play an&#xD;
      important role in IPF exacerbations. The investigators propose to test our central hypothesis&#xD;
      by establishing the efficacy of autoantibody removal by plasma exchange (PEX), in conjunction&#xD;
      with B-cell depletion by rituximab to deplete immunoglobulins and minimize their further&#xD;
      production, among patients with acute IPF exacerbations.&#xD;
&#xD;
      The primary goal of this randomized, multi-center, open-label Phase II clinical trial is to&#xD;
      determine effects of combined plasma exchange (PEX), rituximab, and conventional&#xD;
      corticosteroid administration on selected, relevant immunological parameters, in comparison&#xD;
      to effects of steroids alone, among AE-IPF patients. The investigators anticipate the&#xD;
      findings of this will lead to larger incremental trial(s) to determine actual clinical&#xD;
      efficacy of this treatment.&#xD;
&#xD;
      A total of 40 subjects will be enrolled in this multi-center trial from 5 participating&#xD;
      medical centers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, multi-center, open-label Phase II clinical trial to determine the&#xD;
      efficacy of combined plasma exchange (PEX), rituximab, and conventional corticosteroid&#xD;
      administration, in comparison to corticosteroids alone, among patients with acute IPF&#xD;
      exacerbations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of autoantibody titers</measure>
    <time_frame>Baseline to Day 28</time_frame>
    <description>The primary end-point is reduction of autoantibody titers to cultured human primary pulmonary cells, comparing baseline measures of each individual to results of their measures on day 28, or the latest measure among patients who do not survive to day 28.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IgG concentrations</measure>
    <time_frame>Baseline to Day 60</time_frame>
    <description>Treatment-related effects on plasma IgG concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-cell counts</measure>
    <time_frame>Baseline to Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event (AE) rates</measure>
    <time_frame>Baseline to Day 60</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Arm A - Standard Steroid Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - Experimental Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Steroid Treatment</intervention_name>
    <description>One gm of methylprednisolone i.v., on day 0, followed by 40 mg/day i.v. on days 1-4, and days 6-12 (or the p.o. prednisone equivalent). Methylprednisolone 100 mg i.v. will be administered on days 5 and 13. Steroid doses will then be 20 mg methylprednisolone i.v. (or p.o. prednisone equivalent) from days 14-28, and then reduced thereafter at the discretion of the PI at each site.</description>
    <arm_group_label>Arm A - Standard Steroid Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>The Standard Steroid Treatment, Plasma Exchange and rituximab</intervention_name>
    <description>The Standard Steroid Treatment and, after insertion of a dialysis/apheresis catheter into a central vein, followed by initiation of the PEX and rituximab regimens.</description>
    <arm_group_label>Arm B - Experimental Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          1. A diagnosis of idiopathic pulmonary fibrosis that fulfills American Thoracic Society&#xD;
             Consensus Criteria.1&#xD;
&#xD;
          2. Unexplained worsening or development of dyspnea or hypoxemia within the preceding 30&#xD;
             days.&#xD;
&#xD;
          3. Radiographic imaging showing ground-glass abnormality and/or consolidation&#xD;
             superimposed on a reticular or honeycomb pattern consistent with UIP.&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          1. Diagnosis of documented infection, thromboembolic disease, an additional etiology for&#xD;
             acute lung injury/adult respiratory distress syndrome, congestive heart failure.&#xD;
&#xD;
          2. Presence of active hepatitis B infection.&#xD;
&#xD;
          3. Coagulopathy defined as an INR &gt; 1.8, PTT &gt; 2 x control, and platelet count &lt; 50K.&#xD;
&#xD;
          4. Hyperosmolar state or diabetic ketoacidosis to suggest uncontrolled diabetes mellitus&#xD;
             or uncontrolled hypertension.&#xD;
&#xD;
          5. Hemodynamic instability.&#xD;
&#xD;
          6. History of reaction to blood products, murine-derived products, or prior exposures to&#xD;
             human-murine chimeric antibodies,&#xD;
&#xD;
          7. History of malignancy.&#xD;
&#xD;
          8. Unwillingness to accept a blood transfusion.&#xD;
&#xD;
          9. Unwillingness to agree to full supportive medical care (e.g., intubation) for up to 2&#xD;
             weeks after enrollment.&#xD;
&#xD;
         10. Inability or unwillingness to complete post-treatment surveillance for 60 days.&#xD;
&#xD;
         11. Diagnosis of major comorbidities expected to interfere with subjects study&#xD;
             participation for 28 days.&#xD;
&#xD;
         12. Treatment for &gt;5 days within the preceding month with &gt;20 mg prednisone (or equivalent&#xD;
             dose corticosteroid) or any treatment during the preceding month with a potent&#xD;
             cellular immunosuppressant (e.g., cyclophosphamide, methotrexate, mycophenolate,&#xD;
             azathiaprine, calcineurin inhibitors, etc.) unless the patient has a BAL negative for&#xD;
             opportunistic pathogens (e.g, Pneumocystis, viruses, intracellular organisms,&#xD;
             mycobacteria, etc.).&#xD;
&#xD;
         13. Current treatment with an angiotensin converting enzyme inhibitor that cannot be&#xD;
             discontinued and/or substituted with another antihypertensive agent (to minimize&#xD;
             potential hemodynamic complications during PEX).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Duncan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Medical Center</name>
      <address>
        <city>Philladelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch - Galveston</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Heart and Vascular Institute</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>January 27, 2012</study_first_submitted>
  <study_first_submitted_qc>January 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2012</study_first_posted>
  <last_update_submitted>January 4, 2016</last_update_submitted>
  <last_update_submitted_qc>January 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Idiopathic Pulmonary Fibrosis Exacerbations</keyword>
  <keyword>Idiopathic Pulmonary Fibrosis</keyword>
  <keyword>IPF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

